↓ Skip to main content

Dove Medical Press

Article Metrics

Specific safety and tolerability considerations in the use of anticonvulsant medications in children

Overview of attention for article published in Drug, Healthcare and Patient Safety, July 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
23 Mendeley
Title
Specific safety and tolerability considerations in the use of anticonvulsant medications in children
Published in
Drug, Healthcare and Patient Safety, July 2012
DOI 10.2147/dhps.s28821
Pubmed ID
Authors

Amy Z Crepeau, Brian D Moseley, Elaine C Wirrell

Abstract

Epilepsy is one of the most common neurological disorders in the pediatric age range, and the majority of affected children can be safely and effectively treated with antiepileptic medication. While there are many antiepileptic agents on the market, specific drugs may be more efficacious for certain seizure types or electroclinical syndromes. Furthermore, certain adverse effects are more common with specific classes of medication. Additionally patient-specific factors, such as age, race, other medical conditions, or concurrent medication use may result in higher rates of side effects or altered efficacy. Significant developmental changes in gastric absorption, protein binding, hepatic metabolism, and renal clearance are seen over the pediatric age range, which impact pharmacokinetics. Such changes must be considered to determine optimal dosing and dosing intervals for children at specific ages. Furthermore, approximately one third of children require polytherapy for seizure control, and many more take concurrent medications for other conditions. In such children, drug-drug interactions must be considered to minimize adverse effects and improve efficacy. This review will address issues of antiepileptic drug efficacy, tolerability and ease of use, pharmacokinetics, and drug-drug interactions in the pediatric age range.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 1 4%
Student > Postgraduate 1 4%
Unknown 21 91%
Readers by discipline Count As %
Medicine and Dentistry 2 9%
Unknown 21 91%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2013.
All research outputs
#7,247,680
of 12,073,561 outputs
Outputs from Drug, Healthcare and Patient Safety
#60
of 104 outputs
Outputs of similar age
#61,737
of 112,919 outputs
Outputs of similar age from Drug, Healthcare and Patient Safety
#3
of 6 outputs
Altmetric has tracked 12,073,561 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 104 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 112,919 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.